Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
Not yet recruiting · NCT07831395 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL | Richter transformation | Not yet recruiting | Phase 2 | 2026-09-21 | NCT07831395 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Henan Cancer Hospital | Zhengzhou | China | 67 |
| Jiangsu Province Hospital | Nanjing | China | 39 |
| Nanfang Hospital Southern Medical University | Guangzhou | China | 5 |
| The First Affiliated Hospital of Nanchang University | Nanchang | China | 109 |
| The second Xiangya hospital of central south university | Changsha | China | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | China | 37 |